Glp-1 fusion proteins
CA 2434237 C · Owner: Tschang, Sheng-Hung Rainbow · Inventors: Tschang, Sheng-Hung Rainbow; Glaesner, Wolfgang; Micanovic, Radmilla
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention relates to glucagon-like-1 compounds fused to proteins that have the effect of extending the in vivo half-life of the peptides. These fusion proteins can be used to treat non-insulin dependent diabetes mellitus as well as a variety of other conditions.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed November 29, 2001 and granted May 15, 2012. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended November 29, 2021.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by November 29, 2023.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.